ATE358730T1 - Einzelketten vhh antikörper aus kamelen, verfahren zur deren herstellung in einem saugetier und deren verwendungen - Google Patents

Einzelketten vhh antikörper aus kamelen, verfahren zur deren herstellung in einem saugetier und deren verwendungen

Info

Publication number
ATE358730T1
ATE358730T1 AT02726398T AT02726398T ATE358730T1 AT E358730 T1 ATE358730 T1 AT E358730T1 AT 02726398 T AT02726398 T AT 02726398T AT 02726398 T AT02726398 T AT 02726398T AT E358730 T1 ATE358730 T1 AT E358730T1
Authority
AT
Austria
Prior art keywords
single chain
mammal
camel
production
vhh antibodies
Prior art date
Application number
AT02726398T
Other languages
English (en)
Inventor
Frank Grosveld
Original Assignee
Univ Erasmus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Erasmus filed Critical Univ Erasmus
Application granted granted Critical
Publication of ATE358730T1 publication Critical patent/ATE358730T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
AT02726398T 2001-04-24 2002-04-24 Einzelketten vhh antikörper aus kamelen, verfahren zur deren herstellung in einem saugetier und deren verwendungen ATE358730T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0110029.6A GB0110029D0 (en) 2001-04-24 2001-04-24 Transgenic animal

Publications (1)

Publication Number Publication Date
ATE358730T1 true ATE358730T1 (de) 2007-04-15

Family

ID=9913359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02726398T ATE358730T1 (de) 2001-04-24 2002-04-24 Einzelketten vhh antikörper aus kamelen, verfahren zur deren herstellung in einem saugetier und deren verwendungen

Country Status (16)

Country Link
US (6) US20040137570A1 (de)
EP (2) EP1381630A2 (de)
JP (3) JP4418159B2 (de)
CN (2) CN1520424B (de)
AT (1) ATE358730T1 (de)
AU (1) AU2002256866B2 (de)
BR (2) BR0209204A (de)
CA (2) CA2445253C (de)
CY (1) CY1107669T1 (de)
DE (1) DE60219321T2 (de)
DK (1) DK1414858T3 (de)
ES (1) ES2284863T3 (de)
GB (1) GB0110029D0 (de)
MX (2) MXPA03009776A (de)
PT (1) PT1414858E (de)
WO (2) WO2002085945A2 (de)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
GB0228210D0 (en) * 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20060234340A1 (en) * 2003-02-06 2006-10-19 Novozymes A/S Human heavy chain antibody expression in flamentous fungi
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1737971B1 (de) 2004-01-20 2017-08-16 Merus N.V. Gemische bindender proteine
GB2416768A (en) * 2004-07-22 2006-02-08 Univ Erasmus Heavy chain immunoglobulin complexes
EP1776383B1 (de) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Bindungsmoleküle
US7615218B2 (en) * 2004-09-24 2009-11-10 Washington University Methods for determining and lowering caffeine concentration in fluids
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
GB0601511D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding Molecules 2
TWI404727B (zh) * 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
JP5105468B2 (ja) * 2006-12-05 2012-12-26 独立行政法人産業技術総合研究所 細胞内で機能する抗体の創製および細胞表現型を制御するタンパク質の同定
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
GB0706628D0 (en) * 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
US8568717B2 (en) 2008-04-03 2013-10-29 Vib Vzw Single domain antibodies capable of modulating BACE activity
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
CA2747644C (en) 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
CA2749572A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
PT2491056T (pt) 2009-10-22 2021-10-26 Univ Of Twente Vhh para aplicação na reparação de tecidos, regeneração de órgãos, substituição de órgãos e engenharia de tecidos
WO2011072204A1 (en) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
HRP20251657T1 (hr) 2009-12-14 2026-02-13 Ablynx N.V. Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2552962B1 (de) 2010-03-26 2016-03-23 Ablynx N.V. Einzelne, gegen cxcr7 gerichtete variable immunoglobulindomänen
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
EP2601298B1 (de) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Maüse, die vl domäne enthaltende bindende proteine machen
PL2609119T3 (pl) 2010-08-26 2018-02-28 Agrosavfe N.V. Białka wiążące chitynowy sacharydowy antygen
PY1147875A (es) 2010-11-08 2015-08-03 Novartis Ag Polipéptidos de enlace de los receptores de quimiocina
AU2012234284B2 (en) 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9695227B2 (en) 2011-06-21 2017-07-04 Vrije Universiteit Brussel Binding domains directed against GPCR:G protein complexes and uses derived thereof
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
EP2753644A1 (de) 2011-09-09 2014-07-16 Universiteit Utrecht Holding B.V. Breit neutralisierende vhh gegen hiv-1
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
EP4074833A1 (de) 2011-10-17 2022-10-19 Regeneron Pharmaceuticals, Inc. Mäuse mit eingeschränkten schweren immunglobulinketten
CN102372779A (zh) * 2011-10-25 2012-03-14 李江伟 具有蒜氨酸酶活性的骆驼单域抗体及制备方法和应用
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
EP2617732A1 (de) 2012-01-19 2013-07-24 Vib Vzw Werkzeuge und Verfahren zur Expression von Membranproteinen
CN102660551B (zh) * 2012-02-09 2014-04-16 陈志南 来源于抗CypA骆驼科动物的重链VHH抗体基因、编码多肽及其应用
WO2013138681A1 (en) * 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
SG11201405059XA (en) 2012-03-28 2014-09-26 Kymab Ltd Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
ES2715279T3 (es) 2012-05-24 2019-06-03 Vib Vzw Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
WO2014093908A2 (en) * 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
DK2951201T3 (en) 2013-01-30 2018-01-08 Vib Vzw Novel chimeric polypeptides for screening and drug detection purposes
WO2014122183A1 (en) 2013-02-05 2014-08-14 Vib Vzw Muscarinic acetylcholine receptor binding agents and uses thereof
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
US9617339B2 (en) 2013-03-15 2017-04-11 Vib Vzw Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
CN114732017A (zh) * 2013-04-29 2022-07-12 阿格罗塞文公司 包含结合至鞘脂的抗体的农用化学组合物
WO2014210540A1 (en) 2013-06-28 2014-12-31 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CN103454413B (zh) * 2013-09-04 2015-03-11 吉日木图 双峰驼特异性抗体制备及免疫检测方法
WO2015121092A1 (en) 2014-01-30 2015-08-20 Vib Vzw Opioid receptor binding agents and uses thereof
SG10201808083VA (en) 2014-03-21 2018-10-30 Regeneron Pharma Vl antigen binding proteins exhibiting distinct binding characteristics
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
RS60398B1 (sr) * 2014-04-08 2020-07-31 Regeneron Pharma Ne-humane životinje sa humanizovanim fc-gama receptorima
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
EP3297672B1 (de) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispezifische bindungsproteine und verfahren zur verwendung
RU2749674C2 (ru) 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3334762A1 (de) 2015-08-14 2018-06-20 Allergan, Inc. Schwere-ketten-antikörper gegen pdgf
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
CN109438574B (zh) * 2015-12-25 2020-10-27 中国农业科学院兰州兽医研究所 猪流行性腹泻病毒m蛋白特异性重链抗体
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CN105777894A (zh) * 2016-03-12 2016-07-20 长春力太生物技术有限公司 通过转基因啮齿类动物制备人源化驼类单域抗体的方法
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
EP3455245A2 (de) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutisches targeting von nichtzellulären strukturen
HRP20251020T1 (hr) 2016-05-20 2025-10-24 Harpoon Therapeutics, Inc. Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
EP3332637A1 (de) 2016-12-09 2018-06-13 Universitätsklinikum Hamburg-Eppendorf Vhh-haltiger schwerkettiger antikörper und herstellung davon
CN110139952B (zh) * 2016-12-09 2022-11-25 深圳华大生命科学研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
CA3050715A1 (en) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
JP7077336B2 (ja) 2017-03-24 2022-05-30 ▲寧▼波舜宇光▲電▼信息有限公司 スプリットレンズと撮像モジュール
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
WO2018222587A1 (en) 2017-05-30 2018-12-06 The Regents Of The University Of California NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US10017560B1 (en) 2017-11-16 2018-07-10 King Saud University Nanobody against begomoviruses
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
US12655186B2 (en) 2018-01-26 2026-06-16 Orionis Biosciences, Inc. Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
AU2019241350B2 (en) 2018-03-30 2025-10-02 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
WO2020052543A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3890773A4 (de) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. Modulation von dendritischen zelllinien
EP3930754A4 (de) * 2019-02-27 2023-08-16 Zhejiang Nanomab Technology Center Co. Ltd. Sequenz-basiertes hochdurchsatzverfahren zur erzeugung von camelid-antikörpern zur abdeckung breiter epitope mit hoher auflösung
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
WO2020232303A1 (en) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. EpCAM BINDING PROTEINS AND METHODS OF USE
US20220227888A1 (en) 2019-06-07 2022-07-21 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
CN112574308A (zh) 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
CA3184351A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
WO2022002063A1 (zh) 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 一种4-1bb结合蛋白及其应用
CN116193985A (zh) * 2020-07-13 2023-05-30 加拿大商木曾路生物科技公司 表达重链抗体的转基因动物
TWI885184B (zh) 2020-07-16 2025-06-01 大陸商和鉑醫藥（上海）有限責任公司 Ｐｄ-１抗原結合蛋白及其應用
MX2023006573A (es) 2020-12-03 2023-06-19 Amgen Inc Constructos de inmunoglobulina con multiples dominios de union.
WO2022156908A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method for preparing a lyophilized composition
WO2022156907A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
WO2022157373A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis
EP4294834A2 (de) 2021-02-19 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Einzeldomänenantikörper zur neutralisierung von sars-cov-2
WO2022221120A1 (en) 2021-04-16 2022-10-20 Bio-Techne Corporation Camelid anti-severe acute respiratory syndrome coronavirus antibodies
EP4349867A4 (de) 2021-05-28 2026-01-07 Harbour Biomed Shanghai Co Ltd Spezifisches, auf pd-l1 und cd73 abzielendes bindeprotein
EP4389768A4 (de) 2021-08-18 2025-06-25 Harbour Biomed (Shanghai) Co., Ltd Anti-b7-h4-antikörper und herstellungsverfahren dafür und verwendung davon
US20250009908A1 (en) 2021-10-05 2025-01-09 Vrije Universiteit Brussel Fluorescently Labeled Immunoglobulin Single Variable Domains
US20250188120A1 (en) 2022-03-07 2025-06-12 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
EP4349374A1 (de) 2022-10-05 2024-04-10 Vrije Universiteit Brussel Variable einzeldomänen des anti-urokinase-plasminogenaktivatorrezeptors immunglobulin
US20260103529A1 (en) 2022-10-18 2026-04-16 Confo Therapeutics N.V. Amino Acid Sequences Directed Against the Melanocortin 4 Receptor and Polypeptides Comprising the Same for the Treatment of MC4R-Related Diseases and Disorders
EP4512243A1 (de) 2023-08-21 2025-02-26 Kymab Limited Bindungsmoleküle
CN122094718A (zh) 2023-10-26 2026-05-26 阿布斯因特公司 Her2阳性病灶的图像引导活检

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ID26964A (id) * 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
NZ525664A (en) 2000-11-17 2008-08-29 Kirin Holdings Kk Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
US20020147312A1 (en) * 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
JP3939160B2 (ja) * 2001-05-25 2007-07-04 独立行政法人科学技術振興機構 腎臓における外来遺伝子発現方法
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1513397B1 (de) 2002-05-17 2010-04-14 Kyowa Hakko Kirin Co., Ltd. Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
TWI404727B (zh) * 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除

Also Published As

Publication number Publication date
JP4418159B2 (ja) 2010-02-17
EP1414858B1 (de) 2007-04-04
US8507748B2 (en) 2013-08-13
CA2445253C (en) 2012-04-10
CA2445255A1 (en) 2002-10-31
JP2010013479A (ja) 2010-01-21
CN1520424A (zh) 2004-08-11
JP2005503128A (ja) 2005-02-03
US20110004949A1 (en) 2011-01-06
CN1520424B (zh) 2012-09-05
US20140033335A1 (en) 2014-01-30
DE60219321T2 (de) 2008-03-20
US20040137570A1 (en) 2004-07-15
CY1107669T1 (el) 2013-04-18
EP1381630A2 (de) 2004-01-21
PT1414858E (pt) 2007-05-31
US20110004948A1 (en) 2011-01-06
BR0209204A (pt) 2004-07-06
WO2002085944A3 (en) 2004-03-04
DK1414858T3 (da) 2007-07-09
JP2005503129A (ja) 2005-02-03
ES2284863T3 (es) 2007-11-16
US8502014B2 (en) 2013-08-06
MXPA03009785A (es) 2005-03-07
US20140037616A1 (en) 2014-02-06
DE60219321D1 (de) 2007-05-16
WO2002085945A3 (en) 2003-03-06
AU2002256866B2 (en) 2007-06-21
EP1414858A2 (de) 2004-05-06
WO2002085945A2 (en) 2002-10-31
MXPA03009776A (es) 2005-03-07
WO2002085944A2 (en) 2002-10-31
CA2445253A1 (en) 2002-10-31
US20040142432A1 (en) 2004-07-22
GB0110029D0 (en) 2001-06-13
BR0209207A (pt) 2005-02-09
CN1518559A (zh) 2004-08-04

Similar Documents

Publication Publication Date Title
DE60219321D1 (de) Einzelketten vhh antikörper aus kamelen, verfahren zur deren herstellung in einem saugetier und deren verwendungen
DE602004025805D1 (de) Verfahren zur herstellung von antikörpern
DE60238308D1 (de) Schnellproduktion monoklonaler antikörper
ATE550352T1 (de) Verfahren zur herstellung von hybridantikörper
ATE554390T1 (de) Verfahren zur gewinnung von antikörpern
ATE439380T1 (de) Methoden zur herstellung humaner monoklonaler antikörper
DE60236016D1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
ATE435231T1 (de) Verfahren zur herstellung verzweigterribonukleoside aus 1,2- anhydroribofuranose-zwischenprodukten
DE60106469D1 (de) Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen
DE69901045D1 (de) Verfahren zur Herstellung von Kohlenwasserstoffen aus Synthesegas
ATE407987T1 (de) Neue mesogene, verfahren zu deren herstellung und verwendung
ATE364673T1 (de) Verfahren zur herstellung von dieselbrennstoff aus bitumen und synthesegas
DK1881064T3 (da) HCV-anti-kerne monoklonalt antistof
DE60220792D1 (de) Verfahren zur herstellung von dieselbrennstoff aus bitumen
ATE366710T1 (de) Verfahren zur herstellung von molekularsieben
DE602004025591D1 (de) Verfahren zur herstellung zytotoxischer lymphozyten
ATE544783T1 (de) Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung
DE602006021324D1 (de) Verfahren zur herstellung stabiler b-lymphozyten
DE60214127D1 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
ATE363490T1 (de) Methode zur produktion monoklonaler antikörper
DE69934250D1 (de) Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
ATE370163T1 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
DE60045652D1 (de) Verfahren zur Erzeugung von genetisch veränderten Antikörperherstellungszelllinien mit verbesserter Antikörpereigenschaft
ATE216778T1 (de) Verfahren zur herstellung von konjugaten aus einem spezifischen bindungspartner und einem kohlenhydrathaltigen protein
ATE330781T1 (de) Verfahren zur herstellung eines rohres aus verbundwerkstoffen und hergestelltes rohr

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414858

Country of ref document: EP

EEIH Change in the person of patent owner